Inhibition of angiogenesis by the antifungal drug itraconazole

ACS Chemical Biology

Volumn 2, Issue 4, 2007, Pages 263-270

  Chong, Curtis R ^a   Xu, Jing ^a   Lu, Jun ^a   Bhat, Shridhar ^a   Sullivan Jr , David J ^a,b   Liu, Jun O ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIFUNGAL AGENT; BASIC FIBROBLAST GROWTH FACTOR; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; STEROL 14ALPHA DEMETHYLASE; SULCONAZOLE; TERCONAZOLE; VASCULOTROPIN; VORICONAZOLE; CYTOCHROME P450; LANOSTEROL 14 ALPHA-DEMETHYLASE; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG APPROVAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEREOCHEMISTRY; ANIMAL; CATTLE; CELL CYCLE; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; LEUKEMIA CELL LINE; MALE; NEOVASCULARIZATION (PATHOLOGY); STEREOISOMERISM; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIFUNGAL AGENTS; CATTLE; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; ITRACONAZOLE; JURKAT CELLS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; OXIDOREDUCTASES; STEREOISOMERISM;

EID: 34248598317     PISSN: 15548929     EISSN: None     Source Type: Journal    
DOI: 10.1021/cb600362d     Document Type: Article

References (31)

1. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications, N. Engl. J. Med. 285, 1182-1186.
2. Hanahan, D., and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell 86, 353-364.
3. Folkman, J. (2006) Angiogenesis, Annu. Rev. Med. 57, 1-18.
4. Franson, P. J., and Lapka, D. V. (2005) Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer, Clin. J. Oncol. Nurs. 9, 55-60.
5. Fine, S. L., Martin, D. F., and Kirkpatrick, P. (2005) Pegaptanib sodium, Nat. Rev. Drug Discovery 4, 187-188.
6. Kerbel, R. S. (2006) Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171-1175.
7. Carmeliet, P. (2003) Angiogenesis in health and disease, Nat. Med. 9, 653-660.
8. McCowen, M. C., Callender, M. E., and Lawlis, J. F., Jr. (1951) Fumagillin (H-3), a new antibiotic with amebicidal properties, Science 113, 202-203.
9. Ingber, D., Fujita, T., Kishmoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth, Nature 348, 555-557.
10. D'Amato, R. J., Loughnan, M. S., Flynn, E., and Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis, Proc. Natl. Acad. Sci. U.S.A. 91, 4082-4085.
11. Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., and Tarnawski, A. S. (1999) Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing, Nat. Med. 5, 1418-1423.
12. Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Homung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K. W., and Geissler, E. K. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat. Med. 8, 128-135.
13. Ashbum, T. T., and Thor, K. B. (2004) Drug repositioning: identifying and developing new uses for existing drugs, Nat. Rev. Drug Discovery 3, 673-683.
14. O'Connor, K. A., and Roth, B. L. (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discovery 4, 1005-1014.
15. Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., Toan, S. V., Bruijn, L. I., Su, Z. Z., Gupta, P., and Fisher, P. B. (2005) Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression, Nature 433, 73-77.
16. Chong, C. R., Qian, D. Z., Pan, F., Wei, Y., Pili, R., Sullivan, D. J., Jr., and Liu, J. O. (2006) Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target, J. Med. Chem. 49, 2677-2680.
17. Sheehan, D. J., Hitchcock, C. A., and Sibley, C. M. (1999) Current and emerging azole antifungal agents, Clin. Microbiol. Rev. 12, 40-79.
18. Kunze, K. L., Nelson, W. L., Kharasch, E. D., Thummel, K. E., and Isoherranen, N. (2006) Stereochemical aspects of itraconazole metabolism in vitro and in vivo, Drug Metab. Dispos. 34, 583-590.
19. Vanden Bossche, H., Marichal, P., Gorrens, J., and Coene, M. C. (1990) Biochemical basis for the activity and selectivity of oral antifungal drugs, Br. J. Clin. Pract. Suppl. 71, 41-46.
20. Lamb, D. C., Kelly, D. E., Waterman, M. R., Stromstedt, M., Rozman, D., and Kelly, S. L. (1999) Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents, Yeast 15, 755-763.
21. Trosken, E. R., Adamska, M., Arand, M., Zam, J. A., Patten, C., Volkel, W., and Lutz, W. K. (2006) Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles, Toxicology 228, 24-32.
22. Swinney, D. C., So, O. Y., Watson, D. M., Berry, P. W., Webb, A. S., Kertesz, D. J., Shelton, E. J., Burton, P. M., and Walker, K. A. (1994) Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo, Biochemistry 33, 4702-4713.
23. Burton, P. M., Swinney, D. C., Helter, R., Dunlap, B., Chiou, M., Malonzo, E., Haller, J., Walker, K. A., Salari, A., Murakami, S., Mendizabal, G., and Tokes, L. (1995) Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity, Biochem. Pharmacol. 50, 529-544.
24. Martinez-Botas, J., Suarez, Y., Ferruelo, A. J., Gomez-Coronado, D., and Lasuncion, M. A. (1999) Cholesterol starvation decreases p34(cdc2) kinase activity and arrests the cell cycle at G2, FASEB J. 13, 1359-1370.
25. Fernandez, C., Lobo Md Mdel, V., Gomez-Coronado, D., and Lasuncion, M. A. (2004) Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. Exp. Cell Res. 300, 109-120.
26. Griffith, E. C., Su, Z., Turk, B. E., Chen, S., Chang, Y.-W., Wu, Z., Biemann, K., and Liu, J. O. (1997) Methionine aminopaptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin, Chem. Biol. 4, 461-471.
27. Sin, N., Meng, L., Wang, M. Q. W., Wen, J. J., Bommann, W. G., and Crews, C. M. (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2, Proc. Natl. Acad. Sci. U.S.A. 94, 6099-6103.
28. Pan, F., Means, A. R., and Liu, J. O. (2005) Calmodulin-dependent protein kinase IV regulates nuclear export of Cabin1 during T-cell activation, EMBO J. 24, 2104-2113.
29. Weis, M., Heeschen, C., Glassford, A. J., and Cooke, J. P. (2002) Statins have biphasic effects on angiogenesis, Circulation 105, 739-745.
30. Vincent, L., Soria, C., Mirshahi, F., Opolon, P., Mishal, Z., Vannier, J. P., Soria, J., and Hong, L. (2002) Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models, Arterioscler., Thromb., Vasc. Biol. 22, 623-629.
31. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S., and Martin, G. R. (1992) A simple, quantitive: method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor, Lab Invest 67, 519-528.